Pyrotinib dosing study for HER2-positive advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70 with HER2-positive breast cancer that has spread to other parts of the body (stage IV).
- You have not received any previous cancer treatment for this recurrence or spread.
- You have at least one tumor that can be measured on a scan.
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and thyroid function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
This study tests a targeted therapy called pyrotinib for people with advanced or metastatic HER2-positive breast cancer. It aims to see how well the drug works in a real-world setting, helping guide treatment for this specific type of cancer.
This trial studies a new pre-surgery (neoadjuvant) treatment for HER2-positive breast cancer. It aims to see whether adding Py to HP before surgery can improve how patients’ cancers respond.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.